Pfizer Inc. PFE

Pfizer Inc. (Pfizer) es una empresa biofarmacéutica global basada en la investigación. La compañía se dedica a la investigación, desarrollo, fabricación, comercialización, ventas y distribución de productos biofarmacéuticos. Su cartera global incluye medicamentos y vacunas. La compañía trabaja en diferentes mercados para desarrollar bienestar, prevención, tratamientos y curas. Colabora con proveedores de atención médica, gobiernos y comunidades locales para apoyar y brindar acceso a la atención médica. Sus medicamentos y vacunas proporcionan valor a los proveedores de atención médica y a los pacientes, a través del tratamiento de enfermedades y mejoras en la salud y el bienestar. Vende sus productos farmacéuticos con receta a mayoristas, minoristas, hospitales, clínicas, agencias gubernamentales y farmacias. En Estados Unidos, vende sus productos de vacunas al gobierno federal, a los centros para el control y la prevención de enfermedades (CDC), a mayoristas, consultorios de proveedores individuales, farmacias minoristas y redes integradas de prestación de servicios.

Con 36 acciones de PFE (USD 993,78) habrías recibido USD 61,92 en dividendos en los últimos 12 meses.

• The Motley Fool 2 oct

  Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.

  Pfizer's stock has declined 34% over five years due to falling coronavirus product demand and patent expirations on key drugs. However, the company's recent strategic acquisitions (Seagen, Metsera, Biohaven), regulatory approvals, and cost restructuring efforts are showing positive results. With management confident in maintaining its 6% dividend yield and the stock trading at a reasonable 9.6x forward earnings, the pharmaceutical giant may now present a compelling opportunity for dividend investors.

  

• Zacks Investment Research 1 oct

  Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

  Pfizer (PFE) ended trading at $28.10, down 1.47% and underperforming the S&P 500's 0.2% gain. The company faces declining earnings expectations with Q3 2026 EPS projected at $0.77 (down 11.49% YoY) and full-year earnings expected to fall 7.45%. Despite a discount valuation with a Forward P/E of 9.58 versus industry average of 16.08, Pfizer holds a Zacks Rank #3 (Hold) rating.

  

• Zacks Investment Research 1 oct

  Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

  At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.

  

• Zacks Investment Research 30 sept

  Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?

  Both Moderna and BioNTech are transitioning beyond COVID-19 vaccines into oncology and other therapeutic areas. Moderna has already commercialized RSV and flu vaccines with positive intismeran cancer therapy results, while BioNTech relies more heavily on Comirnaty and has a broader but less advanced oncology pipeline. Moderna is rated as the better investment choice despite trading at a premium valuation, given its further-along transition away from COVID-19 dependency.

  

• GlobeNewswire Inc. 30 sept

  Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

  The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.